Bank Pictet & Cie Europe AG Buys 11,943 Shares of Stryker Corporation $SYK

Bank Pictet & Cie Europe AG boosted its stake in Stryker Corporation (NYSE:SYK) by 8.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,040 shares of the medical technology company’s stock after buying an additional 11,943 shares during the quarter. Stryker makes up about 1.1% of Bank Pictet & Cie Europe AG’s investment portfolio, making the stock its 25th largest position. Bank Pictet & Cie Europe AG’s holdings in Stryker were worth $55,195,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of SYK. Vanguard Group Inc. lifted its holdings in shares of Stryker by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock valued at $12,485,012,000 after acquiring an additional 272,828 shares during the period. State Street Corp boosted its stake in shares of Stryker by 1.0% in the 2nd quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after purchasing an additional 150,204 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Legal & General Group Plc increased its position in shares of Stryker by 4.4% during the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after purchasing an additional 96,662 shares in the last quarter. Finally, Corient Private Wealth LLC increased its position in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Needham & Company LLC boosted their price target on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research report on Friday, January 30th. The Goldman Sachs Group set a $399.00 target price on shares of Stryker in a research note on Friday, January 9th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Finally, TD Cowen cut Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target for the company. in a report on Monday, January 26th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $427.50.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.3%

Shares of NYSE:SYK opened at $329.58 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The firm has a market cap of $126.22 billion, a P/E ratio of 39.24, a P/E/G ratio of 1.92 and a beta of 0.92. Stryker Corporation has a 12 month low of $319.32 and a 12 month high of $404.87. The company’s 50-day moving average price is $358.11 and its two-hundred day moving average price is $362.50.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the previous year, the firm posted $4.01 earnings per share. The company’s revenue was up 11.4% on a year-over-year basis. As a group, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.